Tango Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
TNGX Nasdaq 2834 www.tangotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tango Therapeutics, Inc.

Tango doses first subject in MTAP-deleted and RAS mutant cancer trial - Jun 30th, 2025 3:47 am
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer - Jun 27th, 2025 5:00 am
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - Jun 23rd, 2025 7:07 am
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - May 27th, 2025 5:00 am
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - May 21st, 2025 5:00 am
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - May 15th, 2025 4:38 am
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - May 14th, 2025 4:27 am
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - May 12th, 2025 5:00 am
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Mar 25th, 2025 2:30 pm
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Feb 28th, 2025 3:07 am
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - Feb 27th, 2025 5:00 am
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - Feb 20th, 2025 5:30 am
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Feb 8th, 2025 5:14 am
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - Jan 30th, 2025 5:00 am
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 3rd, 2024 5:00 am
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Nov 27th, 2024 5:00 am
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds - Nov 23rd, 2024 8:26 am
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Nov 8th, 2024 4:05 am
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Nov 6th, 2024 5:05 am
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Nov 6th, 2024 5:00 am